[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-162853-105":53,"doc-detail-162853-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","pre-ind-meeting-package-table-of-contents-application-template","Pre-IND MEETING PACKAGE - Table of Contents - Application Template","","Pre-IND meeting package template for preparing a regulatory milestone request, structured to capture sponsor identity, product and chemical details, and the proposed regulatory pathway and indication. The package includes dosage and administration elements, pediatric study plan and human factors engineering sections when applicable, plus combination product information. A detailed agenda and discussion question list support alignment across administrative, quality, nonclinical, and clinical topics, followed by references, sponsor attendee roster, and a development background to summarize prior communications and substantive changes.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/pre-ind-meeting-package-table-of-contents-application-template/162853/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/pre-ind-meeting-package-table-of-contents-application-template/162853.png","ImageObject",442,249,{"name":88,"@type":89},"Taylor Morgan","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-09-24","2026-08-30",true,{"@type":98,"interactionType":99,"userInteractionCount":73},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What information is required for the Pre-IND meeting package header?","Question",{"text":108,"@type":109},"The template requests sponsor identifiers and affiliations, the sponsoring professor and department, the submission date, and the PIND/application number and sponsor details.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"Which sections cover the product description and regulatory framing?",{"text":113,"@type":109},"It includes product name, chemical name and structure, the proposed regulatory pathway, and the proposed indication, along with required dosage and administration information.",{"name":115,"@type":106,"acceptedAnswer":116},"How does the package structure discussion questions and supporting data?",{"text":117,"@type":109},"It provides a proposed agenda and a list of questions for discussion split into administrative, quality, nonclinical, and clinical areas, followed by data to support discussion with subsections for quality, nonclinical, and clinical plus references.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},162853,1790291471,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":79,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":135,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":79},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","PRE-IND MEETING PACKAGE\nTITLE\nPIND Number\nName of Sponsor, Affiliations\nX Professor, Department\nDUKE UNIVERSTIY\nDurham, NC\nDate of Submission\n\u000f\nTABLE OF CONTENTS\n\u0013 TOC \\o \"1-3\" \\h \\z \\u \u0014\u0013 HYPERLINK \\l \"_Toc15567883\" \u0014TABLE OF CONTENTS\t\u0013 PAGEREF _Toc15567883 \\h \u00142\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567884\" \u0014ABBREVIATIONS\t\u0013 PAGEREF _Toc15567884 \\h \u00143\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567885\" \u00141\tAPPLICATION NUMBER\t\u0013 PAGEREF _Toc15567885 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567886\" \u00142\tPRODUCT NAME\t\u0013 PAGEREF _Toc15567886 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567887\" \u00143\tCHEMICAL NAME AND STRUCTURE\t\u0013 PAGEREF _Toc15567887 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567888\" \u00144\tPROPOSED REGULATORY PATHWAY\t\u0013 PAGEREF _Toc15567888 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567889\" \u00145\tPROPOSED INDICATION\t\u0013 PAGEREF _Toc15567889 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567890\" \u00146\tDOSAGE AND ADMINISTRATION\t\u0013 PAGEREF _Toc15567890 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567891\" \u00146.1\tDosage Form\t\u0013 PAGEREF _Toc15567891 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567892\" \u00146.2\tRoute of Administration\t\u0013 PAGEREF _Toc15567892 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567893\" \u00146.3\tDosing Regimen\t\u0013 PAGEREF _Toc15567893 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567894\" \u00147\tPEDIATRIC STUDY PLANS\t\u0013 PAGEREF _Toc15567894 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567895\" \u00148\tHUMAN FACTORS ENGINEERING PLAN\t\u0013 PAGEREF _Toc15567895 \\h \u00144\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567896\" \u00149\tCOMBINATION PRODUCT INFORMATION\t\u0013 PAGEREF _Toc15567896 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567897\" \u001410\tLIST OF SPONSOR ATTENDEES\t\u0013 PAGEREF _Toc15567897 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567898\" \u001411\tBACKGROUND\t\u0013 PAGEREF _Toc15567898 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567899\" \u001411.1\tHistory of Development Program\t\u0013 PAGEREF _Toc15567899 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567900\" \u001411.2\tSubstantive Changes to Development Plans\t\u0013 PAGEREF _Toc15567900 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567901\" \u001411.3\tCurrent Status of Product Development\t\u0013 PAGEREF _Toc15567901 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567902\" \u001412\tPURPOSE OF MEETING\t\u0013 PAGEREF _Toc15567902 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567903\" \u001413\tPROPOSED AGENDA\t\u0013 PAGEREF _Toc15567903 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567904\" \u001414\tLIST OF QUESTIONS FOR DISCUSSION\t\u0013 PAGEREF _Toc15567904 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567905\" \u001414.1\tAdministrative (Delete if there are no questions in this area)\t\u0013 PAGEREF _Toc15567905 \\h \u00145\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567906\" \u001414.2\tQuality (Delete if there are no questions in this area)\t\u0013 PAGEREF _Toc15567906 \\h \u00146\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567907\" \u001414.3\tNonclinical (Delete if there are no questions in this area)\t\u0013 PAGEREF _Toc15567907 \\h \u00146\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567908\" \u001414.4\tClinical (Delete if there are no questions in this area)\t\u0013 PAGEREF _Toc15567908 \\h \u00146\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567909\" \u001415\tDATA TO SUPPORT DISCUSSION\t\u0013 PAGEREF _Toc15567909 \\h \u00147\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567910\" \u001415.1\tQuality – Manufacturing and Control\t\u0013 PAGEREF _Toc15567910 \\h \u00147\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567911\" \u001415.1.1\tQuality Data and Support\t\u0013 PAGEREF _Toc15567911 \\h \u00147\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567912\" \u001415.1.2\tSynopsis of Proposed Quality Plans\t\u0013 PAGEREF _Toc15567912 \\h \u00148\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567913\" \u001415.2\tNonclinical\t\u0013 PAGEREF _Toc15567913 \\h \u00148\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567914\" \u001415.2.1\tNonclinical Data and Support\t\u0013 PAGEREF _Toc15567914 \\h \u00148\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567915\" \u001415.2.2\tSynopsis of Proposed Nonclinical Studies\t\u0013 PAGEREF _Toc15567915 \\h \u00148\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567916\" \u001415.3\tClinical\t\u0013 PAGEREF _Toc15567916 \\h \u00148\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567917\" \u001415.3.1\tClinical Data and Support\t\u0013 PAGEREF _Toc15567917 \\h \u00148\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567918\" \u001415.3.2\tSynopsis of Proposed Clinical Studies\t\u0013 PAGEREF _Toc15567918 \\h \u00148\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567919\" \u001415.4\tReferences\t\u0013 PAGEREF _Toc15567919 \\h \u001410\u0015\u0015\n\u0013 HYPERLINK \\l \"_Toc15567920\" \u001416\tAPPENDIX\t\u0013 PAGEREF _Toc15567920 \\h \u001411\u0015\u0015\n\u0015\nABBREVIATIONS\n\u000f\nAPPLICATION NUMBER\u0005\nIf unknown, write not applicable.\nPRODUCT NAME\nFor example:\n“Drug XY”-name of the drug\n“Biologic XY”-name of the biologic such as vaccine construct\nCHEMICAL NAME AND STRUCTURE\nThe chemical name, established name, and/o","cbCaio3wN01DcVXI","https://ap.wps.com/l/cbCaio3wN01DcVXI","docx",46079,10,"English","# TABLE OF CONTENTS\n## ABBREVIATIONS\n## APPLICATION NUMBER\n## PRODUCT NAME\n## CHEMICAL NAME AND STRUCTURE\n## PROPOSED REGULATORY PATHWAY\n## PROPOSED INDICATION\n## DOSAGE AND ADMINISTRATION\n## PEDIATRIC STUDY PLANS\n## HUMAN FACTORS ENGINEERING PLAN\n## COMBINATION PRODUCT INFORMATION\n## LIST OF SPONSOR ATTENDEES\n## BACKGROUND\n## PURPOSE OF MEETING\n## PROPOSED AGENDA\n## LIST OF QUESTIONS FOR DISCUSSION\n## DATA TO SUPPORT DISCUSSION\n## APPENDIX","[{\"question\":\"What information is required for the Pre-IND meeting package header?\",\"answer\":\"The template requests sponsor identifiers and affiliations, the sponsoring professor and department, the submission date, and the PIND/application number and sponsor details.\"},{\"question\":\"Which sections cover the product description and regulatory framing?\",\"answer\":\"It includes product name, chemical name and structure, the proposed regulatory pathway, and the proposed indication, along with required dosage and administration information.\"},{\"question\":\"How does the package structure discussion questions and supporting data?\",\"answer\":\"It provides a proposed agenda and a list of questions for discussion split into administrative, quality, nonclinical, and clinical areas, followed by data to support discussion with subsections for quality, nonclinical, and clinical plus references.\"}]","Pre-IND MEETING PACKAGE - Table of Contents - Application Template | DOCX",1788132333]